secwatch.observer — SEC 8-K summary
======================================

Issuer:     Centessa Pharmaceuticals plc (CNTA)
CIK:        0001847903
Form:       8-K
Filed at:   2026-03-31T23:59:59+00:00
Accession:  0001193125-26-134656
Event type: m_and_a
Sentiment:  positive
Materiality: 0.95
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eli Lilly to acquire Centessa for $38/share plus up to $9 in CVRs
-----------------------------------------------------------------

- Centessa shareholders receive $38.00 per share cash plus CVRs worth up to $9.00 per share on milestone achievement.
- CVR milestones: $2 for first US NDA of ORX750/ORX142 by Dec 31, 2029; $5 for IH approval within 5 yrs; $2 for NT2 approval within 5 yrs.
- Supporting shareholders owning ~20% of shares agreed to vote in favor of the scheme.
- Transaction expected to close by Sept 30, 2026, extendable to March 31, 2027 for HSR clearance.
- Termination fee of ~$63M payable by Centessa under certain circumstances.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847903/000119312526134656/0001193125-26-134656-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847903/000119312526134656/d145970d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-134656

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer